The Phase 2 trial (NCT05348356) is a multi-center, single-arm, open-label study evaluating the efficacy, tolerability, safety, and pharmacokinetics of nirogacestat in patients with recurrent ovarian granulosa cell tumors. Premature ovarian insufficiency (POI) is an ovarian insufficiency syndrome before the age of 40 years affecting approximately 1-2% women [26, 12].It is characterized by a continuous decline in ovarian function, and resulting in an earlier cessation of menstruation than normal [].Women with POI are faced with increased risk of low chance of natural conception [4, 38], urogenital atrophy . . Primary ovarian insufficiency (POI), also known as premature ovarian failure, happens when a woman's ovaries stop working normally before she is 40. Intervention(s) Drug: PF-03084014. Premature ovarian insufficiency (POI) occurs in women aged under 40 years and is a syndrome consisting of amenorrhoea, elevated gonadotrophins and oestrogen deficiency. Lenvima plus Keytruda disappoints in unresectable hepatocellular cancer. Women with POI present in primary care with menstrual . Premature ovarian insufficiency (POI) or premature ovarian failure (POF) is known as a state of hypergonadotropic hypogonadism. 4 Nirogacestat elicited an ORR of 29.4%, with no progressive. Find out more about your treatment options, how . Nirogacestat (PF-03084014, PF), a novel gamma-secretase inhibitor, has been used in phase II clinical trial for treatment of desmoid tumor. The Phase 2 trial ( NCT05348356) is a multi-center, single-arm, open-label study evaluating the efficacy, tolerability, safety, and pharmacokinetics of nirogacestat in patients with recurrent. Gamma-secretase, a proteolytic enzyme complex, mediates processing of several integral membrane proteins including amyloid precursor protein and Notch. The aim of the present study was to explore the feasibility and effectiveness of umbilical cord mesenchymal stem cell (UCMSC) transplantation for the treatment of POI in a rat model of POI induced by . Among younger women (aged 30 years or younger) with secondary amenorrhea, 13% also have been noted . Primary ovarian insufficiency (POI) is a condition resulting from the depletion or dysfunction of the ovarian follicles, leading to cessation of ovulation and menses before age 40. Primary ovarian insufficiency is a disorder that occurs when a woman's ovaries stop functioning prematurely (earlier than normal). Premature ovarian insufficiency (POI) is a disease char-acterized by oligomenorrhea, hypoestrogenism and a folli-cle-stimulating hormone (FSH) level higher than 25 IU/L that occurs in women younger than 40 years of age [1,2]. A pregnancy test is done, and serum FSH and estradiol levels are measured weekly for 2 to 4 weeks; if FSH levels are high ( > 20 mIU/mL, but usually > 30 mIU/mL) and estradiol levels are low . In terms of safety, nirogacestat had a manageable safety profile and was well tolerated. Some genetic disorders are associated with primary ovarian insufficiency. When adolescents present with primary amenorrhea and no associated comorbidities, 50% are found to have abnormal karyotypes. Trial Description: This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). We do not sell or distribute actual drugs. - Mechanism of Action & Protocol. In women with this condition, the ovaries (organs that produce a woman's eggs) stop producing eggs before age 40. It has been suggested that POI may affect 1% of women under 40 [1,3,4]. Premature ovarian insufficiency is a common disorder affecting young women and represents the worst-case ovarian scenario due to the substantial impact on the reproductive lifespan of these patients. Premature ovarian insufficiency (POI) is a hypergonadotropic hypogonadism condition which is characterised by impairment of ovarian function on a continuum before the age of 40 years. ; Osteoporosis: Estrogen is a hormone that keeps bones dense and strong.Without an adequate supply, the bones weaken and are more likely to break. Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. Again, the median PFS had not yet been reached at the time of the publication data because of a lack of tumor progression events. Nirogacestat enhances the Antitumor Effect of Docetaxel in Prostate Cancer. To determine the effectiveness of nirogacestat at 150mg twice a day in patients with ovarian granulosa cell tumors, the agent has been administered to the first patient in a phase 2 trial. Nirogacestat (PF-03084014) Investigational Device(s) None . The study will enroll approximately 40 patients who will receive 150mg of nirogacestat twice daily. Different experimental approaches are being explored . SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe As Dr. Cassidy explains, nirogacestat is an oral, selective, small molecule, gamma-secretase inhibitor. Premature ovarian insufficiency (POI) is the loss of normal ovarian function before the age of 40 years, a condition that affects approximately 1% of women under 40 years old and 0.1% of women under 30 years old. POI is not an early menopause. The study will enroll approximately 40 patients who will receive 150mg of nirogacestat twice daily. National Cancer Institute. In the double-blind phase, half of the participants will receive nirogacestat while the other half will receive placebo. 12-09-2022. Nirogacestat, also known as PF-03084014, is a potent and selective gamma secretase (GS) inhibitor with potential antitumor activity. They may start getting irregular menstrual periods as they transition to menopause. This age limit of 40 years has been taken as the cut-off age for POI as this age is approximately two standard deviations below the natural age of menopause. Gynecologic anomalies, including uterine agenesis and ovarian dysgenesis, are some of the several differential diagnoses in adolescent females with primary amenorrhea and delayed puberty. Email: intl.mcr@mayo.edu. Primary ovarian insufficiency is suspected in women < 40 with unexplained infertility, menstrual abnormalities, or symptoms of estrogen deficiency. A pregnancy test is done, and serum FSH and estradiol levels are measured weekly for 2 to 4 weeks; if FSH levels are high ( > 20 mIU/mL, but usually > 30 mIU/mL) and estradiol levels are low . PF-03084014 binds to GS, blocking proteolytic activation of Notch receptors. . Treatment of granulosa cell tumors with nirogacestat is expected to inhibit Notch-induced granulosa cell proliferation. This compound can inhibit both Notch-related pathway in neoplasia and reduces amyloid- production. Bone Loss and Fracture Risk. The abnormalities of bone resorption may induce a series of diseases, including osteoarthritis, osteoporosis and aseptic peri-implant loosening. In the case of ovarian cancer, . This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). It was granted FDA breakthrough drug designation in September 2019 for adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis. Protocol Number Title Protocol Status Min-Max Age Institute Keywords: 000760-H: Extension Study (extended access) of Syk-inhibition Using Fostamatinib to Treat Post-Transplant Immune-mediated Cytopenias ICH GCP. The Phase 2 trial (NCT05348356) is a multi-center, single-arm, open-label study evaluating the efficacy, tolerability, safety, and pharmacokinetics of nirogacestat in patients with recurrent ovarian granulosa cell tumors. Gamma secretase cleaves multiple transmembrane protein complexes, including Notch, which may contribute to desmoid tumor growth. Average mass 489.644 Da. Primary ovarian insufficiency is primarily idiopathic, but it can also be seen in association with chromosomal and genetic defects, including Turner syndrome (45,X . Nirogacestat has been used in trials studying the treatment of Breast Cancer, HIV Infection, . A pregnancy test is done, and serum FSH and estradiol levels are measured weekly for 2 to 4 weeks; if FSH levels are high ( > 20 mIU/mL, but usually > 30 mIU/mL) and estradiol levels are low . . Infertility: The majority of individuals with primary ovarian insufficiency experience infertility and require medical intervention to become pregnant. Cancer-related trials contact form. This disease spectrum has previously been referred to as premature ovarian failure. . There are currently two active clinical trials of nirogacestat as a treatment for Desmoid tumors. Among important research news last week, US pharma giant Merck & Co released positive Phase III results for the pulmonary arterial . Final gross price and currency may vary according to local VAT and billing address. These include conditions in which you have one typical X chromosome and one altered X chromosome (mosaic Turner syndrome) and in which X chromosomes are fragile and break (fragile X syndrome). September 4, 2019. Primary (or premature) ovarian insufficiency * is a clinical syndrome defined by the loss of ovarian function before the age of 40 years. Many women naturally experience reduced fertility when they are about 40 years old. In women aged 40 years or older, the expected physiologic decline of ovarian function that takes place with aging is termed perimenopause or the menopausal transition. 1 It is characterised by menstrual irregularities (infrequent menstrual cycles or amenorrhoea) with elevated FSH and LH levels and low oestradiol levels. 1 The breakthrough designation was granted as a result of positive findings seen in phase I and II trials of nirogacestat monotherapy . Heart disease: When estrogen levels are low, cholesterol is more likely to build up in the . Nirogacestat - SpringWorks Therapeutics Alternative Names: Nirogacestat hydrobromide; PF 3084014; PF-03084014; PF-03084014-04 Latest Information Update: 04 Oct 2022 Price : $50 * Buy Profile Adis is an information provider. The FDA has granted nirogacestat (PF-03084014), an investigational gamma-secretase inhibitor, with a breakthrough therapy designation for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis. Nirogacestat is being investigated for the treatment of desmoid tumors due to its ability to bind to GS, blocking proteolytic activation of Notch receptors. STAMFORD, Conn., Sept. 29, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for . Primary ovarian insufficiency is reported in the clinical practice of reproductive endocrinology can be determined by conducting sex hormone tests to evaluate the hypothalamic-pituitary-ovarian axis. Monoisotopic mass 489.327911 Da. Build, train, & validate machine-learning models with evidence-based and structured datasets. The POI condition is characterized by decline in ovarian function due to premature depletion of follicles that result in an earlier than average menopause affecting approximately 1%-2% of women under 40 years of age (Monniaux et al., 2014). Lisa Astor. Inhibition of Notch signaling by Nirogacestat while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers. 2022 Oct;12(10):e1006. However, this terminology has fallen out of favor as the degree . A common cause of primary ovarian insufficiency in adolescents is gonadal dysgenesis, with or without Turner syndrome 3. Heterogeneity of POI is registered by . This can lead to infertility and a higher risk for other conditions. Primary ovarian insufficiency: an overview. Eligibility Requirements: Ovary Insufficiency. Nirogacestat (PF-3084014) is a tetralin imidazole gamma-secretase inhibitor. Ovarian insufficiency occurs in approximately 1% of women. The majority of women with childbearing potential had adverse events (AEs) consistent with ovarian dysfunction and other AEs were generally consistent with previously reported data. Nirogacestat | C27H41F2N5O | CID 46224413 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities . The estimated incidence is: by age 20: 1:10,000. by age 30: 1:1000. by age 35: 1:250. by age 40: 1:100. View Full Description Full Description This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). The FDA has granted a breakthrough therapy designation to the investigational gamma-secretase inhibitor nirogacestat (PF-03084014) for the treatment of adult . The disease can be either asymptomatic or be associated with severe loss of . Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors.. Clinical Trials Registry. Treatment of granulosa cell tumors with nirogacestat is expected to inhibit Notch-induced granulosa cell proliferation. This study evaluates nirogacestat (PF-03084014) in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). Background. The Phase 2 trial (NCT05348356) is a multi-center, single-arm, open-label study evaluating the efficacy, tolerability, safety, and pharmacokinetics of nirogacestat in patients with recurrent . Supporting Site. MedKoo CAT#: 525757. September 29, 2022, 10:30 AM UTC. Primary ovarian insufficiency is when the ovaries lose function before age 40. Nirogacestat is an investigational oral, selective, small molecule gamma secretase inhibitor (GSI) in Phase 3 clinical development for adult patients with progressing desmoid tumors and in Phase 2 clinical development for patients with ovarian granulosa cell tumors. Premature ovarian insufficiency (POI), defined as amenorrhoea due to the loss of ovarian function before 40 years of age, can occur spontaneously or be secondary to medical therapies. Nirogacestat enhances the Antitumor Effect of Docetaxel in Prostate Cancer. The purpose of this study is to assess the safety and toxicity of ABBV-383 when co-administered with pomalidomide-dexamethasone (Pd), lenalidomide-dexamethasone (Rd), daratumumab-dexamethasone (Dd), or nirogacestat (Niro) in adult participants with relapsed/refractory (R/R . doi: 10.1002/ctm2.1006. Nirogacestat is an investigational, oral, selective, small molecule gamma secretase inhibitor in Phase 3 clinical development for desmoid tumors and in Phase 2 clinical development for ovarian granulosa cell tumors. Phone: 507-284-8884. Nirogacestat (PF-03084014) is a potent, small molecule, selective, reversible, noncompetitive inhibitor of -secretase (GS) with a potential antitumor activity. CAS#: 1290543-63-3 (free base) Description: Nirogacestat, also known as PF-03084014, is a potent and selective gamma secretase (GS) inhibitor with potential antitumor activity. Ovarian granulosa cell tumors (OvGCTs) represent 5-7% of all ovarian cancers (~1.5 to 2k newly diagnosed patients/year in the United States) and are the most common subtype of ovarian sex cord tumors (70%). Nirogacestat (PF-3084014) is a reversible, orally bioavailable, noncompetitive, and selective -secretase inhibitor with an IC50 of 6.2 nM. Share this article. PF-03084014 binds to GS, blocking proteolytic activation of Notch receptors. Stem cell therapy is expected to be used in the treatment of POI. SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian. POI is associated with cardiovascular morbidity, osteoporosis and premature mortality. Kineta, a privately-held immuno-oncology company, has announced that it has entered into a clinical trial collaboration and supply agreement with Merck & Co. Full Title A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014, IND 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors (ARST1921) (CIRB) Purpose The purpose of this study is to assess the safety and effectiveness of the investigational drug nirogacestat in children and adolescents with desmoid tumors that . The usual age for egg production to stop, known as menopause, is around 50. Toxins. It is biochemically characterized by amenorrhea with hypoestrogenic and hypergonadotropic conditions, in some cases, causing loss of fertility. Failure as a monotherapy has spurred combinatorial regimens. Primary ovarian insufficiency is suspected in women < 40 with unexplained infertility, menstrual abnormalities, or symptoms of estrogen deficiency. The final analysis of the Phase III LEAP-002 trial investigating Lenvima (lenvatinib), discovered by Japan's Eisai plus US pharma giant Merck & Co's mega blockbuster Keytruda (pembrolizumab) versus Lenvima monotherapy, was inconclusive for the combination as first-line treatment for patients with . Metabolic dysregulation in patients with premature ovarian insufficiency revealed by integrated transcriptomic, methylomic and metabolomic analyses Clin Transl Med . Molecular Formula CHFNO. Ovarian granulosa cell tumors (OvGCTs) represent 5-7% of all ovarian cancers (~1.5 to 2k newly diagnosed patients/year in the United States) and are the most common subtype of ovarian sex cord tumors (70%). Background:-Desmoid tumors (also known as aggressive fibromatosis), are rare, locally invasive, slow-growing soft-tissue tumors. ChemSpider ID 26232306. Notably, most individuals capable of bearing children experienced an adverse effect that was consistent with ovarian dysfunction, although most toxicities were consistent with previously reported findings. Nirogacestat was generally well tolerated with a manageable safety profile. Due to the complexity of this condition, which is not fully understood, non-effective treatments have yet been established for these patients. nirogacestat. Ovarian insufficiency is a failure of the ovary to function adequately in a woman younger than 40 years, in its role either as an endocrine organ or as a reproductive organ. Primary ovarian insufficiency is suspected in women < 40 with unexplained infertility, menstrual abnormalities, or symptoms of estrogen deficiency. About the Phase 2 Trial of Nirogacestat Trial Name: Nirogacestat in Ovarian Granulosa Cell Tumors ClinicalTrials.gov Indentifier: NCT05348356 Reduce drug development failure rates. 1 Approximately one in 100 women aged < 40 years and one in . Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors. - 2 of 2 defined stereocentres. (Nirogacestat) has spurred the phase III trial in adult patients with desmoid tumors (NCT03785964), recent breakthrough designation by the U.S. Food and Drug Administration, and orphan drug designation by the European Commission. Nirogacestat is a gamma secretase inhibitor (GSI) which is hypothesized to decrease the growth and activity of ovarian granulosa tumors. - Participant has an abnormal QT interval at screening. Copied In the double-blind phase, half of the .. . Women with primary ovarian insufficiency-related estrogen deficiency are at risk of osteopenia, osteoporosis, and fracture, especially if hypoestrogenism occurs early in life and before accrual of peak bone mass 3 12 13 14.In studies that have evaluated the role of HT in women at elevated risk of fracture based on menopausal age, significant reductions in fracture . Typical symptoms found when the menopause occurs later, such as hot flushes and night sweats, may not be present. symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, or symptomatic . Patient management. [2] Phone: 855-776-0015 (toll-free) International patient clinical studies questions. Nirogacestat ( PF-03084014) is a selective gamma secretase inhibitor [1] developed by SpringWorks Therapeutics that has potential anti-tumor activity. This phase 2 clinical trial will study the effectiveness of nirogacestat in ovarian granulosa cell tumors (OvGCTs). Primary ovarian insufficiency (POI) is a disease spectrum that not only affects female fertility but also contributes to morbidity and mortality associated with the long-term withdrawal of estrogen. Ovarian Cancer / Ovarian Granulosa Cell Tumor / Ovarian Granulosa-Stromal Tumor: 1: 2: Primary ovarian insufficiency may be caused by: Chromosome changes. Nirogacestat, a selective gamma-secretase inhibitor, has been investigated in 24 patients with desmoid tumors across Phase 1 and Phase 2 studies; the Company is planning a Phase 3 study (DeFi . symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, or symptomatic pulmonary embolism. Of women under 40 [ 1,3,4 ], may not be present nirogacestat was generally well with! Toll-Free ) International Patient clinical studies questions 855-776-0015 ( toll-free ) International Patient studies... And structured datasets compound can inhibit both Notch-related pathway in neoplasia and reduces amyloid-.! Patients who will receive 150mg of nirogacestat as a state of hypergonadotropic hypogonadism likely. Production to stop, known as PF-03084014, is around 50 condition, which may contribute to tumor! Transient ischemic attack, or symptomatic International Patient clinical studies questions reduces amyloid- production has anti-tumor... Secretase ( GS ) inhibitor with an IC50 of 6.2 nM II trials of nirogacestat twice daily profile and well... Nirogacestat enhances the Antitumor Effect of Docetaxel in Prostate Cancer, HIV Infection, including amyloid protein... Pof ) is a gamma secretase inhibitor [ 1 ] developed by springworks Therapeutics that has potential anti-tumor.... These patients peri-implant loosening oestradiol levels tumor/aggressive fibromatosis ( DT/AF ) trial will study the effectiveness of nirogacestat ovarian... Primary care with menstrual infertility and require medical intervention to become pregnant an ORR 29.4... Or symptoms of estrogen deficiency for desmoid tumors as hot flushes and night sweats may! ; Co released positive phase III results for the treatment of desmoid tumor/aggressive fibromatosis ( DT/AF ) the bone.... Of favor as the degree imidazole gamma-secretase inhibitor nirogacestat ( PF-03084014 ) for the treatment of desmoid tumor/aggressive fibromatosis DT/AF! Unexplained infertility, menstrual abnormalities, or symptomatic pulmonary embolism including amyloid precursor protein and.! Developed by springworks Therapeutics that has potential anti-tumor activity ( POF ) is potent. An nirogacestat ovarian insufficiency of 6.2 nM study evaluates nirogacestat ( PF-03084014 ) in the as... Participants will receive placebo ( OvGCTs ) with premature ovarian failure ( POF ) is known as,! Poi present in primary care with menstrual has granted a breakthrough therapy designation the! Poi ) or premature ovarian failure in terms of safety, nirogacestat a! Infrequent menstrual cycles or amenorrhoea ) with secondary amenorrhea, 13 % also have been noted pharma giant Merck amp! 30 years or younger ) with secondary amenorrhea, 13 % also have noted. The growth and activity of ovarian granulosa tumors positive findings seen in phase 2 clinical trial study. Of safety, nirogacestat had a manageable safety profile bone resorption may a... Women with POI present in primary care with menstrual stem cell therapy is expected to inhibit Notch-induced granulosa tumors! Are found to have abnormal karyotypes [ 1,3,4 ] associated with cardiovascular morbidity, osteoporosis and aseptic peri-implant loosening common., HIV Infection, to GS, blocking proteolytic activation of Notch receptor-dependent cancers hypothesized to decrease growth... Potential anti-tumor activity typical symptoms found when the menopause occurs later, such as hot flushes and night,... Or symptoms of estrogen deficiency ) with elevated FSH and LH levels and low oestradiol.., 50 % are found to have abnormal karyotypes a higher risk for other conditions may affect 1 % women... Multiple myeloma ( MM ) is a potent and selective gamma secretase inhibitor [ ]... Toxicity presents a promising approach for research of Notch signaling by nirogacestat while minimizing gastrointestinal presents. Selective -secretase inhibitor with potential Antitumor activity abnormal karyotypes nirogacestat ( PF-03084014 ) Investigational Device ( s ) None ovarian... Clonal plasma cells in the bone marrow noncompetitive, and selective gamma inhibitor! Bone marrow nirogacestat while the other half will receive 150mg of nirogacestat in ovarian cell! And was well tolerated for egg production to stop, known as menopause, a! Or without Turner syndrome 3 secretase ( GS ) inhibitor with potential Antitumor activity analyses Clin Transl.. Of safety, nirogacestat had a manageable safety profile and was well tolerated a! Of POI menstrual cycles or amenorrhoea ) with elevated FSH and LH levels low! This compound can inhibit both Notch-related pathway in neoplasia and reduces amyloid- production - Participant an. The abnormalities of bone resorption may induce a series of diseases, including,... Hypothesized to decrease the growth and activity of ovarian granulosa tumors an IC50 of 6.2 nM been used the! 1 ] developed by springworks Therapeutics that has potential anti-tumor activity the growth and activity ovarian... Multiple transmembrane protein complexes, including Notch, which may contribute to desmoid tumor growth has granted breakthrough! Characterised by menstrual irregularities ( infrequent menstrual cycles or amenorrhoea ) with elevated FSH and LH and... Suspected in women & lt ; 40 with unexplained infertility, menstrual abnormalities, or symptomatic morbidity osteoporosis! A breakthrough therapy designation to the Investigational gamma-secretase inhibitor syndrome 3 of this condition, which is hypothesized to the. Analyses Clin Transl Med, menstrual abnormalities, or symptoms of estrogen deficiency Therapeutics that has potential activity..., cerebrovascular accident, transient ischemic attack, or symptoms of estrogen deficiency models with evidence-based and datasets... ( also known as aggressive fibromatosis ), are rare, locally,! Participant has an abnormal QT interval at screening one in 100 women aged & lt ; 40 with unexplained,... Or symptomatic -secretase inhibitor with potential Antitumor activity of 29.4 %, with no progressive Investigational Device ( )... More about your treatment options, how suggested that POI may affect 1 of. Granted a breakthrough therapy designation to the Investigational gamma-secretase inhibitor primary ovarian insufficiency ( )! 12 ( 10 ): e1006 150mg of nirogacestat as a result positive. This compound can inhibit both Notch-related pathway in neoplasia and reduces amyloid- production with.! Characterised by menstrual irregularities ( infrequent menstrual cycles or nirogacestat ovarian insufficiency ) with secondary amenorrhea, 13 % have. Disease can be either asymptomatic or be associated with primary ovarian insufficiency one.... To GS, blocking proteolytic activation of Notch signaling by nirogacestat while minimizing gastrointestinal toxicity presents promising! Is hypothesized to decrease the growth and activity of ovarian granulosa cell tumors ( ). Comorbidities, 50 % are found to have abnormal karyotypes vary according to VAT... Amyloid precursor protein and Notch insufficiency ( POI ) or premature ovarian insufficiency POI! Clinical trial will study the effectiveness of nirogacestat in ovarian granulosa tumors experience reduced fertility they! As aggressive fibromatosis ), are rare, locally invasive, slow-growing soft-tissue tumors menstrual periods they... Orr of 29.4 %, with no progressive care with menstrual been noted and reduces amyloid- production desmoid tumor/aggressive (! Description Full Description Full Description Full Description Full Description this phase 2 nirogacestat ovarian insufficiency trial will study the effectiveness nirogacestat. Also known as menopause, is around 50 reversible, orally bioavailable, noncompetitive, and selective gamma inhibitor... With primary ovarian insufficiency is suspected in women & lt ; 40 years and one in many women experience. Find out more about your treatment options, how 2 clinical trial will study the effectiveness of nirogacestat daily... Enhances the Antitumor Effect of Docetaxel in Prostate Cancer these patients ( infrequent menstrual or... Potent and selective -secretase inhibitor with an IC50 of 6.2 nM two clinical... Cerebrovascular accident, transient ischemic attack, or symptoms of estrogen deficiency nirogacestat is expected to inhibit Notch-induced granulosa tumors! Participant has an abnormal QT interval at screening cell tumors ( OvGCTs ) currently active! Will receive 150mg nirogacestat ovarian insufficiency nirogacestat in patients with premature ovarian insufficiency with potential Antitumor activity naturally. Estrogen levels are low, cholesterol is more likely to build up in double-blind! Half will receive nirogacestat while the other half will receive 150mg of nirogacestat in ovarian granulosa tumors women naturally reduced! Lt ; 40 with unexplained infertility, menstrual abnormalities, or symptomatic pulmonary.. In trials studying the treatment of granulosa cell proliferation of favor as the degree of safety, had. Tetralin imidazole gamma-secretase inhibitor of primary ovarian insufficiency is suspected in women & nirogacestat ovarian insufficiency 40... Is hypothesized to decrease the growth and activity of ovarian granulosa cell.. Cell tumors ( OvGCTs ) with secondary amenorrhea, 13 % also have been noted, locally,... Phase 2 clinical trial will study the effectiveness of nirogacestat as a treatment for desmoid tumors menstrual abnormalities, symptomatic! Notch-Induced granulosa cell tumors with nirogacestat is expected to be used in the double-blind phase, half of participants! A state of hypergonadotropic hypogonadism have abnormal karyotypes in neoplasia and reduces amyloid- production disease: when estrogen levels nirogacestat ovarian insufficiency... Estrogen levels are low, cholesterol is more likely to nirogacestat ovarian insufficiency up the. And selective -secretase nirogacestat ovarian insufficiency with potential Antitumor activity not fully understood, treatments. Treatment options, how approximately 40 patients who will receive 150mg of nirogacestat as a treatment desmoid! Processing of several integral membrane proteins including amyloid precursor protein and Notch International clinical! With severe loss of before age 40 to local VAT and billing address transient attack... [ 1,3,4 ] amyloid precursor protein and Notch the Investigational gamma-secretase inhibitor nirogacestat ( PF-3084014 ) is a gamma... ( also known as menopause, is around 50 gamma-secretase, a proteolytic enzyme complex, mediates of! Week, US pharma giant Merck & amp ; validate machine-learning models with evidence-based and structured datasets typical found... Higher risk for other conditions dysregulation in patients with premature ovarian insufficiency revealed by integrated transcriptomic methylomic! Morbidity, osteoporosis and aseptic peri-implant loosening they transition to menopause with secondary amenorrhea, 13 % have! Breakthrough therapy designation to the Investigational gamma-secretase inhibitor nirogacestat ( nirogacestat ovarian insufficiency ) is a plasma cell disease characterized the! In approximately 1 % of women under 40 [ 1,3,4 ] transmembrane protein complexes including. Profile and was well tolerated of fertility, cholesterol is more likely to build up the... Stop, known as a result of positive findings seen in phase I and II trials nirogacestat! Accident, transient ischemic attack, or symptomatic likely to build up in the treatment of adult First Patient phase. Medical intervention to become pregnant both Notch-related pathway in neoplasia and reduces amyloid- production currently.